(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 22.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Adc Therapeutics Sa's revenue in 2025 is $75,209,000.On average, 8 Wall Street analysts forecast ADCT's revenue for 2025 to be $9,684,588,661, with the lowest ADCT revenue forecast at $9,198,990,386, and the highest ADCT revenue forecast at $10,093,507,004. On average, 8 Wall Street analysts forecast ADCT's revenue for 2026 to be $10,059,316,922, with the lowest ADCT revenue forecast at $8,400,478,528, and the highest ADCT revenue forecast at $11,966,528,923.
In 2027, ADCT is forecast to generate $18,757,472,148 in revenue, with the lowest revenue forecast at $15,088,232,120 and the highest revenue forecast at $23,907,043,652.